Symbols / VRAX
VRAX Chart
About
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.53M |
| Enterprise Value | -1.79M | Income | -5.64M | Sales | 2.99K |
| Book/sh | 0.81 | Cash/sh | 0.53 | Dividend Yield | — |
| Payout | 0.00% | Employees | 19 | IPO | — |
| P/E | — | Forward P/E | -0.86 | PEG | — |
| P/S | 513.62 | P/B | 0.25 | P/C | — |
| EV/EBITDA | 0.32 | EV/Sales | -598.28 | Quick Ratio | 9.89 |
| Current Ratio | 11.35 | Debt/Eq | 10.60 | LT Debt/Eq | — |
| EPS (ttm) | -1.22 | EPS next Y | -0.24 | EPS Growth | — |
| Revenue Growth | -67.50% | Earnings | — | ROA | -48.40% |
| ROE | -83.82% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -1607.88% | Profit Margin | 0.00% | Shs Outstand | 7.42M |
| Shs Float | 6.16M | Short Float | 0.93% | Short Ratio | 0.14 |
| Short Interest | — | 52W High | 1.95 | 52W Low | 0.20 |
| Beta | 1.67 | Avg Volume | 5.36M | Volume | 147.92K |
| Target Price | $1.00 | Recom | None | Prev Close | $0.21 |
| Price | $0.21 | Change | -1.20% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$1.00
Mean price target
2. Current target
$0.20
Latest analyst target
3. DCF / Fair value
$-8.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.20
Low
$1.00
High
$1.00
Mean
$1.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $1 |
| 2025-03-31 | init | HC Wainwright & Co. | — → Buy | $3 |
- Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PR Newswire Wed, 03 Dec 2025 08
- Virax Biolabs (Nasdaq: VRAX) announces $5 million private placement for working capital - Stock Titan Wed, 03 Dec 2025 08
- Is VRAX stock a safe buy before earnings - 2025 Performance Recap & Community Driven Trade Alerts - mfd.ru Sat, 14 Feb 2026 02
- Why Is Virax Biolabs (VRAX) Stock Rocketing Higher Today? - TipRanks Wed, 03 Dec 2025 08
- Virax Biolabs stock rockets after clinical progress in post-infection diagnostics - Investing.com Wed, 03 Dec 2025 08
- Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why - Yahoo Finance hu, 15 Jan 2026 08
- Virax Biolabs (VRAX) Falls 18% on Lack of Leads - Yahoo Finance Wed, 27 Aug 2025 07
- Virax Biolabs Sets March 11, 2026 AGM to Vote on Reverse Share Split and New Equity Plan - TipRanks Fri, 30 Jan 2026 08
- Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PR Newswire hu, 04 Dec 2025 08
- What are VRAX’s recent SEC filings showing - July 2025 Closing Moves & Fast Moving Stock Watchlists - mfd.ru Wed, 11 Feb 2026 05
- Virax Biolabs Releases Interim Financial Results for September 2025 - TipRanks ue, 02 Dec 2025 08
- Is VRAX stock risky to hold now - 2025 Major Catalysts & Real-Time Volume Triggers - mfd.ru Mon, 09 Feb 2026 00
- Virax Biolabs Partners with Emory University on ViraxImmuneâ„¢ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PR Newswire ue, 26 Aug 2025 07
- VRAX Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- How analysts rate VRAX stock today - July 2025 Analyst Calls & Verified Technical Trade Signals - mfd.ru Wed, 11 Feb 2026 05
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.80M | -6.22M | -5.44M | -1.73M |
| TotalUnusualItems | 0.00 | -390.36K | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -390.36K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.06M | -6.73M | -5.46M | -1.71M |
| ReconciledDepreciation | 343.39K | 103.10K | 0.00 | 0.00 |
| ReconciledCostOfRevenue | 59.40K | 105.83K | 9.93K | 0.00 |
| EBITDA | -5.80M | -6.61M | -5.44M | -1.73M |
| EBIT | -6.15M | -6.71M | -5.44M | -1.73M |
| NetInterestIncome | -58.18K | -26.88K | -15.47K | -15.44K |
| InterestExpense | 58.18K | 26.88K | 15.47K | 15.44K |
| NormalizedIncome | -6.06M | -6.34M | -5.46M | -1.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.06M | -6.73M | -5.46M | -1.71M |
| TotalExpenses | 6.17M | 6.26M | 5.74M | 1.73M |
| TotalOperatingIncomeAsReported | -6.16M | -6.50M | -5.73M | -1.73M |
| DilutedAverageShares | 3.73M | 2.01M | 1.06M | 1.14M |
| BasicAverageShares | 3.73M | 2.01M | 1.06M | 1.14M |
| DilutedEPS | -1.62 | -3.36 | -5.13 | -1.50 |
| BasicEPS | -1.62 | -3.36 | -5.13 | -1.50 |
| DilutedNIAvailtoComStockholders | -6.06M | -6.73M | -5.46M | -1.71M |
| NetIncomeCommonStockholders | -6.06M | -6.73M | -5.46M | -1.71M |
| NetIncome | -6.06M | -6.73M | -5.46M | -1.71M |
| MinorityInterests | 5.99K | 5.58K | 269.00 | 41.04K |
| NetIncomeIncludingNoncontrollingInterests | -6.07M | -6.74M | -5.46M | -1.75M |
| NetIncomeContinuousOperations | -6.07M | -6.74M | -5.46M | -1.75M |
| TaxProvision | -136.66K | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -6.20M | -6.74M | -5.46M | -1.75M |
| OtherIncomeExpense | 17.18K | -606.12K | 290.47K | -753.00 |
| OtherNonOperatingIncomeExpenses | 17.18K | -215.77K | 290.47K | -753.00 |
| SpecialIncomeCharges | 0.00 | -390.36K | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 390.36K | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | -58.18K | -26.88K | -15.47K | -15.44K |
| InterestExpenseNonOperating | 58.18K | 26.88K | 15.47K | 15.44K |
| OperatingIncome | -6.16M | -6.11M | -5.73M | -1.73M |
| OperatingExpense | 6.11M | 6.16M | 5.73M | 1.73M |
| ResearchAndDevelopment | 1.78M | 1.56M | 2.18M | 433.74K |
| SellingGeneralAndAdministration | 4.33M | 4.59M | 3.55M | 1.30M |
| SellingAndMarketingExpense | 26.62K | 13.82K | 57.20K | |
| GeneralAndAdministrativeExpense | 4.33M | 4.59M | 3.55M | 1.30M |
| OtherGandA | 4.33M | 4.59M | 3.55M | 1.30M |
| GrossProfit | -53.07K | 50.59K | -1.36K | 0.00 |
| CostOfRevenue | 59.40K | 105.83K | 9.93K | 0.00 |
| TotalRevenue | 6.33K | 156.42K | 8.56K | 0.00 |
| OperatingRevenue | 6.33K | 156.42K | 8.56K | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 4.34M | 2.57M | 1.55M | 1.14M |
| ShareIssued | 4.34M | 2.57M | 1.55M | 1.14M |
| TotalDebt | 377.00K | 224.30K | 146.25K | |
| TangibleBookValue | 5.70M | 5.37M | 8.95M | -974.58K |
| InvestedCapital | 5.73M | 5.37M | 9.27M | -974.58K |
| WorkingCapital | 4.22M | 4.21M | 8.73M | -1.20M |
| NetTangibleAssets | 5.70M | 5.37M | 8.95M | -974.58K |
| CapitalLeaseObligations | 344.54K | 224.30K | 0.00 | |
| CommonStockEquity | 5.70M | 5.37M | 9.13M | -974.58K |
| TotalCapitalization | 5.70M | 5.37M | 9.13M | -974.58K |
| TotalEquityGrossMinorityInterest | 5.46M | 5.14M | 8.90M | -1.20M |
| MinorityInterest | -233.97K | -227.98K | -222.40K | -222.13K |
| StockholdersEquity | 5.70M | 5.37M | 9.13M | -974.58K |
| OtherEquityInterest | -54.50K | |||
| GainsLossesNotAffectingRetainedEarnings | 30.28M | 23.89M | 20.92M | 5.36M |
| OtherEquityAdjustments | 30.28M | 23.89M | 20.92M | |
| RetainedEarnings | -24.59M | -18.53M | -11.79M | -6.34M |
| CapitalStock | 4.34K | 2.57K | 1.56K | 999.00 |
| CommonStock | 4.34K | 2.57K | 1.56K | 999.00 |
| TotalLiabilitiesNetMinorityInterest | 964.75K | 345.19K | 908.40K | 1.25M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 291.54K | 176.34K | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 291.54K | 176.34K | 0.00 | |
| LongTermCapitalLeaseObligation | 291.54K | 176.34K | 0.00 | |
| CurrentLiabilities | 673.21K | 168.85K | 908.40K | 1.25M |
| CurrentDeferredLiabilities | 0.00 | 38.25K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 38.25K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 85.46K | 47.95K | 146.25K | |
| CurrentCapitalLeaseObligation | 52.99K | 47.95K | 0.00 | |
| CurrentDebt | 32.47K | 146.25K | ||
| OtherCurrentBorrowings | 32.47K | |||
| CurrentNotesPayable | 0.00 | 146.25K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 60.48K | 0.00 | 409.71K | 0.00 |
| PayablesAndAccruedExpenses | 527.26K | 120.89K | 314.19K | 1.25M |
| CurrentAccruedExpenses | 126.54K | 63.12K | 121.99K | 269.00K |
| Payables | 400.72K | 57.77K | 192.20K | 976.41K |
| DuetoRelatedPartiesCurrent | 337.58K | 0.00 | 18.30K | 129.94K |
| TotalTaxPayable | 7.05K | 12.14K | 14.00K | 0.00 |
| AccountsPayable | 56.09K | 45.63K | 159.91K | 846.47K |
| TotalAssets | 6.43M | 5.48M | 9.81M | 48.71K |
| TotalNonCurrentAssets | 1.53M | 1.10M | 178.40K | 0.00 |
| GoodwillAndOtherIntangibleAssets | 0.00 | 178.40K | 0.00 | |
| OtherIntangibleAssets | 178.40K | |||
| NetPPE | 1.53M | 1.10M | 0.00 | |
| AccumulatedDepreciation | -442.31K | -103.10K | -11.10K | |
| GrossPPE | 1.98M | 1.21M | 11.10K | |
| OtherProperties | 1.90M | 1.15M | ||
| MachineryFurnitureEquipment | 70.77K | 61.63K | 11.10K | |
| CurrentAssets | 4.89M | 4.38M | 9.63M | 48.71K |
| PrepaidAssets | 539.38K | 512.78K | 281.48K | 6.00K |
| Inventory | 94.67K | 60.38K | 0.00 | 20.95K |
| FinishedGoods | 0.00 | 60.38K | 0.00 | 20.95K |
| WorkInProcess | 44.72K | 0.00 | ||
| RawMaterials | 49.96K | 0.00 | ||
| Receivables | 30.65K | 217.84K | 0.00 | 0.00 |
| TaxesReceivable | 30.65K | 217.84K | 0.00 | |
| AccountsReceivable | 0.00 | 928.00 | ||
| AllowanceForDoubtfulAccountsReceivable | 0.00 | 0.00 | ||
| GrossAccountsReceivable | 0.00 | 928.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 4.23M | 3.59M | 9.35M | 21.76K |
| CashAndCashEquivalents | 4.23M | 3.59M | 9.35M | 21.76K |
| CashFinancial | 4.23M | 3.59M | 9.35M | 21.76K |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.17M | -7.41M | -4.36M | -809.07K |
| RepaymentOfDebt | -107.76K | -206.27K | -341.25K | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 487.50K | 100.00K |
| IssuanceOfCapitalStock | 5.13M | 234.00 | 13.65M | 519.61K |
| CapitalExpenditure | -603.89K | -1.16M | -178.40K | |
| InterestPaidSupplementalData | 78.95K | 6.10K | 15.47K | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 4.23M | 3.59M | 9.35M | 21.76K |
| BeginningCashPosition | 3.59M | 9.35M | 21.76K | 17.62K |
| ChangesInCash | 639.70K | -5.76M | 9.33M | 4.13K |
| FinancingCashFlow | 5.81M | 1.65M | 13.69M | 813.21K |
| CashFlowFromContinuingFinancingActivities | 5.81M | 1.65M | 13.69M | 813.21K |
| NetOtherFinancingCharges | -18.30K | -111.64K | 193.59K | 585.20K |
| ProceedsFromStockOptionExercised | 786.74K | 1.87M | 0.00 | 0.00 |
| NetCommonStockIssuance | 5.13M | 234.00 | 13.65M | 519.61K |
| CommonStockIssuance | 5.13M | 234.00 | 13.65M | 519.61K |
| NetIssuancePaymentsOfDebt | -107.76K | -206.27K | 146.25K | 100.00K |
| NetShortTermDebtIssuance | 0.00 | -149.91K | 146.25K | 100.00K |
| ShortTermDebtPayments | 0.00 | -149.91K | -341.25K | 0.00 |
| ShortTermDebtIssuance | 0.00 | 0.00 | 487.50K | 100.00K |
| NetLongTermDebtIssuance | -107.76K | -56.37K | 0.00 | |
| LongTermDebtPayments | -107.76K | -56.37K | 0.00 | |
| InvestingCashFlow | -603.89K | -1.16M | -178.40K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -603.89K | -1.16M | -178.40K | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -211.95K | -178.40K | 0.00 |
| PurchaseOfIntangibles | 0.00 | -211.95K | -178.40K | 0.00 |
| NetPPEPurchaseAndSale | -603.89K | -952.50K | 0.00 | 0.00 |
| PurchaseOfPPE | -603.89K | -952.50K | 0.00 | 0.00 |
| OperatingCashFlow | -4.56M | -6.25M | -4.18M | -809.07K |
| CashFlowFromContinuingOperatingActivities | -4.56M | -6.25M | -4.18M | -809.07K |
| ChangeInWorkingCapital | 625.62K | -1.12M | -182.33K | 644.39K |
| ChangeInOtherWorkingCapital | -38.25K | 38.25K | ||
| ChangeInPayablesAndAccruedExpense | 466.85K | -572.25K | 33.94K | 641.16K |
| ChangeInPayable | 466.85K | -572.25K | 33.94K | 641.16K |
| ChangeInAccountPayable | 466.85K | -572.25K | 33.94K | 641.16K |
| ChangeInPrepaidAssets | -26.60K | -231.31K | -275.48K | 2.19K |
| ChangeInInventory | -34.29K | -60.38K | 20.95K | 121.00 |
| ChangeInReceivables | 219.66K | -217.84K | 0.00 | 928.00 |
| ChangesInAccountReceivables | 32.47K | 0.00 | 0.00 | 928.00 |
| OtherNonCashItems | 45.60K | 115.50K | 20.00K | 296.35K |
| StockBasedCompensation | 365.31K | 1.01M | 1.73M | 0.00 |
| AssetImpairmentCharge | 0.00 | 390.36K | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 343.39K | 103.10K | 0.00 | 0.00 |
| DepreciationAndAmortization | 343.39K | 103.10K | 0.00 | 0.00 |
| Depreciation | 343.39K | 103.10K | 0.00 | 0.00 |
| OperatingGainsLosses | 123.74K | -8.80K | -294.27K | 61.00 |
| NetForeignCurrencyExchangeGainLoss | 123.74K | 3.67K | 111.00 | 5.66K |
| NetIncomeFromContinuingOperations | -6.07M | -6.74M | -5.46M | -1.75M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for VRAX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|